Sign In
close X
The user name and password you entered does not match
the information we have on file.
Forgot your password?
Contact us
close X
Please enter a valid code.
Contact us
Showing Results for [onc] leukemia
Narrow Results
Content Types
NCI Clinical Trials
Looking for trials? Go to NCI and browse 8,000+ trials
41 Search Results
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Pediatric Radiation Oncology
Pediatric Radiation Oncology
Perez and Brady’s Principles and Practice of Radiation Oncology
Perez and Brady’s Principles and Practice of Radiation Oncology
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Principles of Molecular Diagnostics and Personalized Cancer Medicine
Principles of Molecular Diagnostics and Personalized Cancer Medicine
Principles of Molecular Diagnostics and Personalized Cancer Medicine
Principles of Molecular Diagnostics and Personalized Cancer Medicine
Principles of Molecular Diagnostics and Personalized Cancer Medicine
Principles of Molecular Diagnostics and Personalized Cancer Medicine
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Chapter 11. Cancer Stem Cells >
Leukemia Stem Cells
Based on the depth of knowledge gained from more than four decades of research in normal hematopoiesis, it is not surprising that identification of CSCs was first achieved in a ...
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Chapter 16. RNA Viruses >
Human T-Lymphotropic Virus Type 1
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Chapter 46. Antisense Agents >
Clinical Trials of G3139 (Oblimersen) in Chronic Lymphocytic Leukemia
Increasing evidence suggests that the pathogenesis of chronic lymphocytic leukemia is linked to Bcl-2 overexpression.15 High levels of Bcl-2 expression have been correlated with resistance to chemotherapy, and in the ...
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Chapter 124. Leukemias and Lymphomas of Childhood >
Leukemias (updated 4/4/2013)
Cancer: Principles & Practice of Oncology
Cancer: Principles & Practice of Oncology
Chapter 142. Transplantation-Related Malignancies >
Myelodysplasia and Acute Myeloid Leukemia
Therapy-related myelodysplasia (t-MDS) and therapy-related acute myeloid leukemia (t-AML) have emerged as the major cause of nonrelapse mortality in patients undergoing autologous HCT for Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma.4,14 ...
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chapter 14. Classical Alkylating Agents >
Treatment-Related Leukemias
Treatment-related or secondary leukemia, usually acute myelogenous leukemia (AML), often preceded by myelodysplastic syndrome (MDS), arises in patients who have a history of exposure to alkylating agents. Cases of secondary leukemia have been ...
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chapter 18. Topoisomerase II Inhibitors: Anthracyclines >
Secondary Leukemia
A second important late toxicity of anthracyclines, and particularly doxorubicin, is secondary leukemia. As previously discussed, this class of drugs is mutagenic. It produces single- and double-strand breaks in DNA through its inhibition ...
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chapter 19. Topoisomerase II Inhibitors: The Epipodophyllotoxins >
Delayed Toxicity: Etoposide-Induced Secondary Leukemia
The increased frequency of illegitimate recombination events induced by Top2-reactive agents may account for their leukemogenicity20 (see Chapter 42). Etoposide was demonstrated to be mutagenic in patients.152 The Childhood Cancer Survivor Study (CCSS) has ...
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chapter 29. Molecular  Targeted Drugs >
Chronic Myelogenous Leukemia
Imatinib is approved for treatment of patients with CML.24 It produces hematologic responses in the vast majority (>95%) of CML patients in chronic phase, either previously untreated or refractory to ...
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chapter 31. Cytokine Therapy for Cancer >
Hematologic Malignancies: Hairy Cell Leukemia
Type I IFNs have had their most clinical success against two hematologic malignancies: hairy cell leukemia (HCL) and CML. A regimen of IFNα-2b 2 million units/m2 subcutaneously three times a ...
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chapter 34. Thalidomide and its Analogs in the Treatment of Hematologic Malignancies, Including Multiple Myeloma, and Solid Tumors >
Acute Myelogenous Leukemia
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chapter 38. Hematopoietic Growth Factors >
Acute Leukemia and Myelodysplastic Syndrome
The CSFs have been used after induction chemotherapy, priming before induction chemotherapy, and after consolidation chemotherapy in patients with AML. The use of CSFs before chemotherapy as priming therapy to ...
Human Radiation Injury
Human Radiation Injury
Chapter 8. Atomic-Bomb Survivors: Long-term Health Effects of Radiation >
Leukemia
By the late 1940s, there were suggestions of an increased risk of leukemia among the atomic survivors, and hematologists in Hiroshima and Nagasaki formed the Leukemia Registry to monitor cases ...
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Chapter 8. Intraventricular and Intrathecal Therapy >
Adult Acute Myelogenous Leukemia
Although CNS relapse in adult AML is not common (1.5% to 8%),79 one group performed an uncontrolled study of cytosine arabinoside (100 mg) or MTX (15 mg) intraventricularly every 4 ...
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Chapter 11. Hematopoietic Stem Cell Transplantation >
Indications for Transplantation
The indications for transplantation are not always clear-cut in each patient's clinical situation. However, a number of diseases are generally accepted as being indications for transplantation. The relative use of ...
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Chapter 24. Second Malignancies after Chemotherapy >
Acute Leukemia After Hodgkin Lymphoma
The treatment of Hodgkin lymphoma disease with radiation chemotherapy and combination chemotherapy is one of the great triumphs of modern cancer therapy. In 1960, the diagnosis of Hodgkin lymphoma meant ...
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Chapter 24. Second Malignancies after Chemotherapy >
Autologous Stem Cell Transplantation
High-dose chemotherapy with autoSCT has been used to treat high-risk Hodgkin lymphoma, NHL, MM, and breast cancer. Several transplant centers have published their rates of t-MDS/t-AML after transplant185–202 (Table 24-3). ...
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Chapter 24. Second Malignancies after Chemotherapy >
Chronic Lymphocytic Leukemia
The evidence that chemotherapy increases the risk of leukemia in chronic lymphocytic leukemia (CLL) patients comes mainly from case reports and clinical trials but has yet to be confirmed by ...
Perry’s The Chemotherapy Source Book, 5e
Perry’s The Chemotherapy Source Book, 5e
Chapter 46. Management of Myeloproliferative Disorders and Chronic Myeloid Leukemia >
Chronic Myeloid Leukemia
CML is caused by an acquired oncogenic mutation (BCR-ABL1 fusion) of the hematopoietic stem cell and is characterized by left-shifted granulocytosis, marked splenomegaly, and constitutional symptoms.49 The disease has a ...
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chapter 8. Antifolates > Intracellular Transformation
A decrease in MTX PGs was found in small cell ...
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chapter 10. Cytidine Analogues > Cytosine Arabinoside
Ara-C is one of the most effective agents in the ...
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chapter 10. Cytidine Analogues > Aza-Cytidine Analogs
5-Aza-analogs of cytidine have become important therapeutic agents and tools ...
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Cancer Chemotherapy and Biotherapy: Principles and Practice
Didn't find what you were looking for?
Run a full-text search on 'leukemia'
Terms of Use  |  Privacy  |  Help/Contact  |  Feedback
Copyright © Lippincott Williams & Wilkins. All Rights Reserved.